Sri Lankan pharmaceutical company Morison, formerly J.L Morison Son & Jones (Ceylon) PLC, is making significant strides in domestic drug production. Following a recent Rs. 400 million upgrade to their Mutwal facility and a substantial Rs. 4 billion investment in a new state-of-the-art plant in Homagama, Morison is poised to revolutionize the Sri Lankan pharmaceutical landscape.
The Homagama facility, opened in 2022, boasts the title of the largest pharmaceutical manufacturing investment in Sri Lanka. It adheres to rigorous European Union Good Manufacturing Practices (EU GMP) and implements a first-of-its-kind zero liquid discharge effluent treatment system. This commitment to quality and environmental responsibility ensures the production of world-class medication.
Morison has already introduced five “Made in Sri Lanka” tablets and syrups to the local market, with plans to expand their offerings to ten more products by the end of the year. These domestically produced drugs are not only cost-effective, but also demonstrably bring down the prices of imported alternatives. Their groundbreaking EmpaMor tablets, for instance, are priced at nearly half the cost of their imported counterparts.
Despite a strong presence in supplying bulk generic drugs to government hospitals and private doctors, Morison acknowledges a need for broader brand recognition. The company is launching a major campaign to encourage the medical community to embrace locally manufactured pharmaceuticals.
This dedication to domestic production stems from a desire to reduce Sri Lanka’s reliance on foreign pharmaceutical imports and conserve valuable foreign exchange. Morison’s commitment to quality, affordability, and environmental responsibility positions them as a leader in Sri Lanka’s growing pharmaceutical industry.